Sunday 11 October 2026
Export all BMY data to Excel Powerpack
Bristol Myers Squibb Company
BMY Healthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 5.74%, EPS grew 153.1%, free cash flow fell 13.2% and total debt fell 12.3%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.
59.12
0.46
−0.77%
Follow BMY
Bristol Myers Squibb Company 8-K filed Nov 3, 2025
8.01 Other events; 9.01 Financial statements and exhibits